134 related articles for article (PubMed ID: 36580122)
1. Inhaled treprostinil vs iloprost: Comparison of adherence, persistence, and health care resource utilization in patients with pulmonary arterial hypertension.
Burger CD; Wu B; Classi P; Morland K
J Manag Care Spec Pharm; 2023 Jan; 29(1):101-108. PubMed ID: 36580122
[No Abstract] [Full Text] [Related]
2. Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis.
Song C; Kunovszki P; Beaudet A
J Health Econ Outcomes Res; 2022; 9(1):151-160. PubMed ID: 35800882
[No Abstract] [Full Text] [Related]
3. Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States.
Burger CD; Ozbay AB; Lazarus HM; Riehle E; Montejano LB; Lenhart G; White RJ
J Manag Care Spec Pharm; 2018 Aug; 24(8):834-842. PubMed ID: 29436260
[TBL] [Abstract][Full Text] [Related]
4. Comparative evaluation of costs and healthcare resource utilization of oral selexipag versus inhaled treprostinil or oral treprostinil in patients with pulmonary arterial hypertension.
Papademetriou E; Liu X; Beaudet A; Tsang Y; Potluri R; Panjabi S
J Med Econ; 2023; 26(1):644-655. PubMed ID: 37086091
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of prostacyclins in pulmonary arterial hypertension.
Roman A; Barberà JA; Escribano P; Sala ML; Febrer L; Oyagüez I; Sabater E; Casado MA
Appl Health Econ Health Policy; 2012 May; 10(3):175-88. PubMed ID: 22452448
[TBL] [Abstract][Full Text] [Related]
6. Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension.
Bourge RC; Tapson VF; Safdar Z; Benza RL; Channick RN; Rosenzweig EB; Shapiro S; White RJ; McSwain CS; Gotzkowsky SK; Nelsen AC; Rubin LJ
Cardiovasc Ther; 2013 Feb; 31(1):38-44. PubMed ID: 22970909
[TBL] [Abstract][Full Text] [Related]
7. Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin.
Wright EE; Malone DC; Trujillo JM; Gill J; Huse S; Li X; Zhou FL; Preblick R; Reid T
J Manag Care Spec Pharm; 2022 Jun; 28(6):592-603. PubMed ID: 35352995
[No Abstract] [Full Text] [Related]
8. Prostacyclin Use Among Patients with Pulmonary Arterial Hypertension in the United States: A Retrospective Analysis of a Large Health Care Claims Database.
Burger CD; Pruett JA; Lickert CA; Berger A; Murphy B; Drake W
J Manag Care Spec Pharm; 2018 Mar; 24(3):291-302. PubMed ID: 29406840
[TBL] [Abstract][Full Text] [Related]
9. The direct and indirect health care costs associated with pulmonary arterial hypertension among commercially insured patients in the United States.
Ogbomo A; Tsang Y; Mallampati R; Panjabi S
J Manag Care Spec Pharm; 2022 Jun; 28(6):608-616. PubMed ID: 35621726
[No Abstract] [Full Text] [Related]
10. Medication Adherence and Healthcare Costs Among Patients with Pulmonary Arterial Hypertension Treated with Oral Prostacyclins: A Retrospective Cohort Study.
Dean BB; Saundankar V; Stafkey-Mailey D; Anguiano RH; Nelsen AC; Gordon K; Classi P
Drugs Real World Outcomes; 2020 Sep; 7(3):229-239. PubMed ID: 32144746
[TBL] [Abstract][Full Text] [Related]
11. Health Care Costs and Thromboembolic Events in Hydroxyurea-Treated Patients with Polycythemia Vera.
Parasuraman SV; Shi N; Paranagama DC; Bonafede M
J Manag Care Spec Pharm; 2018 Jan; 24(1):47-55. PubMed ID: 29290171
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
[TBL] [Abstract][Full Text] [Related]
13. Inhaled iloprost as an add-on therapy for advanced pulmonary arterial hypertension: An Indian perspective.
Bobhate P; Gupta RK; Karande T; Kulkarni S
Natl Med J India; 2022; 35(6):338-343. PubMed ID: 37167510
[TBL] [Abstract][Full Text] [Related]
14. The economic burden of HIV-associated wasting in the era of modern antiretroviral therapy.
Siddiqui J; Samuel SK; Hayward B; Wirka KA; Deering KL; Harshaw Q; Phillips A; Harbour M
J Manag Care Spec Pharm; 2022 Oct; 28(10):1180-1189. PubMed ID: 35939048
[No Abstract] [Full Text] [Related]
15. Ambulatory Transition from Parenteral Prostanoid to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension.
Kimmig LM; Liao C; Bag R
Lung; 2020 Feb; 198(1):53-58. PubMed ID: 31912412
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of clinical characteristics, health care resource utilization, and cost outcomes of hemophilia A carriers and noncarriers in the United States: A real-world comparative analysis.
Xing S; Batt K; Kuharic M; Bullano M; Caicedo J; Chakladar S; Markan R; Farahbakhshian S
J Manag Care Spec Pharm; 2023 Jun; 29(6):626-634. PubMed ID: 37276033
[No Abstract] [Full Text] [Related]
17. Economic burden and antidepressant treatment patterns among patients with major depressive disorder in the United States.
Zhu L; Ferries E; Suthoff E; Namjoshi M; Bera R
J Manag Care Spec Pharm; 2022 Nov; 28(11-a Suppl):S2-S13. PubMed ID: 36242598
[No Abstract] [Full Text] [Related]
18. Resource utilization at the time of prostacyclin initiation in children in pulmonary arterial hypertension: a multicenter analysis.
Hart SA; Arora G; Feingold B
Pulm Circ; 2018; 8(1):2045893217753357. PubMed ID: 29313743
[TBL] [Abstract][Full Text] [Related]
19. Prolonged oral corticosteroid treatment in patients with systemic lupus erythematosus: An evaluation of 12-month economic and clinical burden.
Huang SP; DerSarkissian M; Gu YM; Duh MS; Wang MJ; Benson J; Vu J; Averell C; Bell CF
J Manag Care Spec Pharm; 2023 Apr; 29(4):365-377. PubMed ID: 36989451
[No Abstract] [Full Text] [Related]
20. Inhaled treprostinil sodium for the treatment of pulmonary arterial hypertension.
Ferrantino M; White RJ
Expert Opin Pharmacother; 2011 Nov; 12(16):2583-93. PubMed ID: 21988216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
